Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Apr. 19];7(6):s257. Available from: https://skin.dermsquared.com/skin/article/view/2404